Genocea Biosciences (GNCA) Likely To See Advancement Of GEN-009, Reit Outperform at Baird
Tweet Send to a Friend
Baird analyst Michael Ulz reiterated an Outperform rating and $15.00 price target on Genocea Biosciences (NASDAQ: GNCA) after last Friday’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
